Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06237062 | Not yet recruiting | Migraine

Migraine Survey in Gulf Region
Sponsor:

Novartis Pharmaceuticals

Brief Summary:

The objective of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients newly started on erenumab over 12 weeks

Condition or disease

Migraine

Intervention/treatment

erenumab

Detailed Description:

This is a longitudinal prospective descriptive primary data collection using a 20 min online survey. Patients will be selected by investigators (general neurologists, headache/migraine specialists) in primary care clinics and hospitals. After fulfilling the inclusion criteria, the patient will be asked to sign an online informed consent. A 5 min screener will follow after which the patient will be directed through a link to the full survey. The duration of data collection will be for 6 months since the start of survey rolling in each site across centers in the Gulf Region.}}

Study Type : Observational
Estimated Enrollment : 200 participants
Official Title : Real-world Experience of Patients Newly Started on Erenumab in the Gulf Region: a Longitudinal Prospective Observational Study
Actual Study Start Date : April 30, 2024
Estimated Primary Completion Date : January 30, 2025
Estimated Study Completion Date : January 30, 2025

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 100 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • EM& CM (with or without Medication Overuse Headache (MOH)) patients
  • Newly Started on erenumab either 70 mg or 140 mg (first dose received within 1 month prior study enrollment and baseline endpoints collection)
  • Ability to receive 3 monthly doses of erenumab.
  • Age more than 18 years
  • Males and Females
  • Allowing the patients to be stable on 1 adjunctive migraine preventive medication (if present)
  • Agreed to be included in the study and signed informed consent
Exclusion Criteria
  • Less than 18 years
  • Age at onset of Migraine more than 50 years
  • Any contraindications to the start of erenumab as per label
  • Refusal to sign informed consent
  • Inability to participate or restricted access to the online survey
  • Enrolled in an interventional migraine-related study at the time of the study enrollement
Migraine Survey in Gulf Region

Location Details

Please Choose a site

Migraine Survey in Gulf Region

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations